Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression in adults: LQD a pragmatic randomised controlled trial
Health Technol Assess. 2025 May;29(12):1-118. doi: 10.3310/YQVF5347. ABSTRACT BACKGROUND: Lithium and several atypical antipsychotics are the recommended first-line augmentation options for treatment-resistant depression; however, few studies have compared them directly,…
Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression in adults: LQD a pragmatic randomised controlled trial
Health Technol Assess. 2025 May;29(12):1-118. doi: 10.3310/YQVF5347. ABSTRACT BACKGROUND: Lithium and several atypical antipsychotics are the recommended first-line augmentation options for treatment-resistant depression; however, few studies have compared them directly,…
Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression in adults: LQD a pragmatic randomised controlled trial
Health Technol Assess. 2025 May;29(12):1-118. doi: 10.3310/YQVF5347. ABSTRACT BACKGROUND: Lithium and several atypical antipsychotics are the recommended first-line augmentation options for treatment-resistant depression; however, few studies have compared them directly,…
Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression in adults: LQD a pragmatic randomised controlled trial
Health Technol Assess. 2025 May;29(12):1-118. doi: 10.3310/YQVF5347. ABSTRACT BACKGROUND: Lithium and several atypical antipsychotics are the recommended first-line augmentation options for treatment-resistant depression; however, few studies have compared them directly,…
Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression in adults: LQD a pragmatic randomised controlled trial
Health Technol Assess. 2025 May;29(12):1-118. doi: 10.3310/YQVF5347. ABSTRACT BACKGROUND: Lithium and several atypical antipsychotics are the recommended first-line augmentation options for treatment-resistant depression; however, few studies have compared them directly,…
Bedtime vs Morning Antihypertensive Medications in Frail Older Adults: The BedMed-Frail Randomized Clinical Trial
JAMA Netw Open. 2025 May 1;8(5):e2513812. doi: 10.1001/jamanetworkopen.2025.13812. ABSTRACT IMPORTANCE: The effect of antihypertensive administration time on major adverse cardiovascular events is unclear, and has never been studied in frail…
Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression in adults: LQD a pragmatic randomised controlled trial
Health Technol Assess. 2025 May;29(12):1-118. doi: 10.3310/YQVF5347. ABSTRACT BACKGROUND: Lithium and several atypical antipsychotics are the recommended first-line augmentation options for treatment-resistant depression; however, few studies have compared them directly,…
Bedtime vs Morning Antihypertensive Medications in Frail Older Adults: The BedMed-Frail Randomized Clinical Trial
JAMA Netw Open. 2025 May 1;8(5):e2513812. doi: 10.1001/jamanetworkopen.2025.13812. ABSTRACT IMPORTANCE: The effect of antihypertensive administration time on major adverse cardiovascular events is unclear, and has never been studied in frail…
Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression in adults: LQD a pragmatic randomised controlled trial
Health Technol Assess. 2025 May;29(12):1-118. doi: 10.3310/YQVF5347. ABSTRACT BACKGROUND: Lithium and several atypical antipsychotics are the recommended first-line augmentation options for treatment-resistant depression; however, few studies have compared them directly,…
Bedtime vs Morning Antihypertensive Medications in Frail Older Adults: The BedMed-Frail Randomized Clinical Trial
JAMA Netw Open. 2025 May 1;8(5):e2513812. doi: 10.1001/jamanetworkopen.2025.13812. ABSTRACT IMPORTANCE: The effect of antihypertensive administration time on major adverse cardiovascular events is unclear, and has never been studied in frail…